Skip to content

BIOQUEST CORP.: 10-Q filed 2022-05-27

What BIOQUEST CORP. reported in its quarterly report filed 2022-05-27 (fiscal Q3 2022): 21 published measures, 71 facts as tagged in accession 0001493152-22-015291.

This filing

Form
10-Q (quarterly report)
Filed
2022-05-27
Fiscal period
fiscal Q3 2022
Accession
0001493152-22-015291 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOQUEST CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-01-31116USD
At 2021-04-3017,097USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-01-31393,674USD
At 2021-04-301,786,638USD
At 2021-01-31393,458USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-01-31-393,558USD
At 2021-10-31-443,652USD
At 2021-07-31-2,141,586USD
At 2021-04-30-1,769,541USD
At 2021-01-31-1,445,378USD
At 2020-10-31-803,090USD
At 2020-07-31-360,809USD
At 2020-04-30-138,579USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-01-31116USD
At 2021-04-30260USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-11-01 to 2022-01-3150,094USD92
2021-05-01 to 2022-01-31-574,890USD276
2021-08-01 to 2021-10-31-187,939USD92
2021-05-01 to 2021-07-31-437,045USD92
2020-11-01 to 2021-01-31-667,288USD92
2020-05-01 to 2021-01-31-1,619,798USD276
2020-08-01 to 2020-10-31-630,281USD92
2020-05-01 to 2020-07-31-322,230USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-05-01 to 2022-01-31-65,144USD276
2020-05-01 to 2021-01-31-188,106USD276

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-05-01 to 2022-01-3165,000USD276
2020-05-01 to 2021-01-31188,000USD276

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-01-31-10,418,760USD
At 2021-04-30-9,843,870USD
At 2021-01-31-393,558USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2021-11-01 to 2022-01-3111,310,230shares92
2021-05-01 to 2022-01-319,788,912shares276
2020-11-01 to 2021-01-318,345,733shares92
2020-05-01 to 2021-01-318,181,833shares276

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2021-11-01 to 2022-01-3111,586,448shares92
2021-05-01 to 2022-01-319,788,912shares276
2020-11-01 to 2021-01-318,345,733shares92
2020-05-01 to 2021-01-318,181,833shares276

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2021-11-01 to 2022-01-310.004USD/shares92
2021-05-01 to 2022-01-31-0.059USD/shares276
2020-11-01 to 2021-01-31-0.08USD/shares92
2020-05-01 to 2021-01-31-0.198USD/shares276

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2021-11-01 to 2022-01-310.004USD/shares92
2021-05-01 to 2022-01-31-0.059USD/shares276
2020-11-01 to 2021-01-31-0.08USD/shares92
2020-05-01 to 2021-01-31-0.198USD/shares276

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-05-01 to 2021-01-31150,000USD276

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-11-01 to 2022-01-3152,721USD92
2021-05-01 to 2022-01-31-588,059USD276
2020-11-01 to 2021-01-31-564,626USD92
2020-05-01 to 2021-01-31-1,515,428USD276

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-01-31116USD
At 2021-04-3017,097USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2021-11-01 to 2022-01-314,098USD92
2021-05-01 to 2022-01-3162,347USD276
2020-11-01 to 2021-01-3116,887USD92
2020-05-01 to 2021-01-3118,595USD276

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-01-31393,674USD
At 2021-04-301,786,638USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-11-01 to 2022-01-31-52,721USD92
2021-05-01 to 2022-01-31588,059USD276
2020-11-01 to 2021-01-31564,626USD92
2020-05-01 to 2021-01-311,515,428USD276

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-01-3111,310,230shares
At 2021-04-308,730,733shares

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-11-01 to 2022-01-31-5,416USD92
2021-05-01 to 2022-01-3145,887USD276
2020-11-01 to 2021-01-3143,943USD92
2020-05-01 to 2021-01-3198,902USD276

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-05-01 to 2022-01-3165,000USD276
2020-05-01 to 2021-01-31135,000USD276

Inspect the source

Entity
BIOQUEST CORP. / CIK 0001568628
Captured
SEC response SHA-256
b8d01618ea9a5bbbd320ce08a47649720a9b6e8f13d0a715d03d0c201a302796

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001568628.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))